Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
223RaCl2 Treatment in mCRPC with 68Ga-PSMA PET Response Evaluation
2017-001395-38Phase 2Terminated
- Sponsor
- Azienda USL della Valle d'Aosta
- Start
- Nov 2020
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Alpha Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of radium-223 dichloride in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Azienda USL della Valle d'Aosta. Primary endpoints: Primary: Treatment response by 68Ga-PSMA PET and Primary: Comparison with bone scintigraphy. Started Nov 2020; status: terminated.
02
Drugs
radium-223 dichloride
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2017-001395-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001395-38.